TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05652920: A Phase Ib/II, Open-Label, Multi-Center Study to Investigate the Safety, PK, and Efficacy of Ori-C101 in Advanced Hepatocellular Carcinoma (HCC) Patients (BEACON)

Sponsor: OriCell Therapeutics Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 105 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,673,130

Rescue Site Savings

+$3,102,330

Unlock Full NCT05652920 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05652920 Rescue Dossier →